Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multiple-Site, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose (SAD) Study to Assess the Safety and Tolerability of Inhaled SNSP113 in Healthy Male Subjects (Part A) and Subjects With Stable Cystic Fibrosis (Part B)

NCT03309358 is registered in ClinicalTrials.gov with Synspira, Inc. as lead sponsor.

NCT NCT03309358
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03309358 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multiple-Site, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose (SAD) Study to Assess the Safety and Tolerability of Inhaled SNSP113 in Healthy Male Subjects (Part A) and Subjects With Stable Cystic Fibrosis (Part B)
Lead sponsor
Synspira, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
September 28, 2017
Completion date
December 18, 2017
Enrollment
32 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

antibiotic resistant infection, burkholderia cepacia infection, burkholderia infections, cystic fibrosis, cystic fibrosis lung, cystic fibrosis pulmonary exacerbation, cystic fibrosis with exacerbation, lung diseases, lung infection, lung infection pseudomonal, lung inflammation, lung; infection, atypical mycobacterium, multi-antibiotic resistance, pulmonary disease, pulmonary inflammation, respiratory tract disease